Traws Pharma
TRAW
34 hedge funds and large institutions have $6.14M invested in Traws Pharma in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 2 increasing their positions, 12 reducing their positions, and 10 closing their positions.
259% more call options, than puts
Call options by funds: $176K | Put options by funds: $49K
0% more funds holding
Funds holding: 34 → 34 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
0.06% less ownership
Funds ownership: 0.53% → 0.46% (-0.06%)
39% less capital invested
Capital invested by funds: $10.1M → $6.14M (-$3.95M)
83% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$950K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$467K |
| 3 |
Renaissance Technologies
New York
|
+$430K |
| 4 |
Two Sigma Investments
New York
|
+$218K |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
+$149K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$958K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$588K |
| 3 |
PVI
Pura Vida Investments
New York
|
-$575K |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$493K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$240K |
TRAW Hedge Fund Activity: Q4 2021 in Review
34 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q4 2021, worth a combined $6.14M — down 39% from $10.1M a quarter earlier.
Fund positioning in TRAW was balanced in Q4 2021: 10 funds opened new positions, 10 closed out, 2 added to existing stakes and 12 trimmed.
The largest buyer was Two Sigma Advisers, opening a new position worth an estimated $950K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $958K sold.
- 34 institutional investors held Traws Pharma (TRAW) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $6.14M of Traws Pharma stock for Q4 2021, down 39% quarter-over-quarter.
- 10 funds opened new Traws Pharma positions in Q4 2021 and 10 closed out, a net change of 0 holders.
- The largest Traws Pharma buyer in Q4 2021 was Two Sigma Advisers, an estimated $950K added.
- The largest Traws Pharma seller in Q4 2021 was Alyeska Investment Group, an estimated $958K sold.
Based on aggregated 13F filings for Q4 2021.